ArticleEndocrinology, diabetes & metabolism2021

A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.

Lyndon Marc Evans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.